Fortune 500 rank: 168
2008 revenue: $15 billion
2008 total shareholder return: 24.4%
Analysts grew bullish when Amgen's osteoporosis drug, denosumab, showed promising clinical trial results. But even the top biotech company's stable of existing drugs posted better-than-expected sales in 2008.
NEXT: Omnicare
Last updated April 20 2009: 1:34 PM ET